92 related articles for article (PubMed ID: 12669395)
1. [Cost-effectiveness of weekly paclitaxel for patients with advanced non-small cell lung cancer].
Suyama H; Hitsuda Y; Matsumoto S; Nakamoto M; Shigeoka Y; Nakanishi H; Igishi T; Burioka N; Yasuda K; Sako T; Miyata M; Endo M; Shimizu E
Gan To Kagaku Ryoho; 2003 Mar; 30(3):365-70. PubMed ID: 12669395
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer.
Evans WK; Le Chevalier T
Eur J Cancer; 1996 Dec; 32A(13):2249-55. PubMed ID: 9038606
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC.
Evans WK
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):18-25; discussion 25-6. PubMed ID: 9556779
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer.
Hillner BE; Smith TJ
Semin Oncol; 1996 Apr; 23(2 Suppl 5):25-30. PubMed ID: 8610234
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
Earle CC; Evans WK
Br J Cancer; 1999 May; 80(5-6):815-20. PubMed ID: 10360660
[TBL] [Abstract][Full Text] [Related]
6. Vinorelbine in advanced non-small cell lung cancer. A pharmacoeconomic review.
Coukell AJ; Noble S; Faulds D
Pharmacoeconomics; 1999 Apr; 15(4):405-17. PubMed ID: 10537959
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
Plosker GL; Hurst M
Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer.
Thongprasert S; Permsuwan U; Ruengorn C; Charoentum C; Chewaskulyong B
Asia Pac J Clin Oncol; 2011 Dec; 7(4):369-75. PubMed ID: 22151987
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of paclitaxel (Taxol) + cisplatin is similar to that of teniposide + cisplatin in advanced non-small cell lung cancer: a multicountry analysis.
Annemans L; Giaccone G; Vergnenègre A
Anticancer Drugs; 1999 Jul; 10(6):605-15. PubMed ID: 10885909
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.
Smith TJ; Hillner BE; Neighbors DM; McSorley PA; Le Chevalier T
J Clin Oncol; 1995 Sep; 13(9):2166-73. PubMed ID: 7666075
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.
Kelly K; Crowley J; Bunn PA; Presant CA; Grevstad PK; Moinpour CM; Ramsey SD; Wozniak AJ; Weiss GR; Moore DF; Israel VK; Livingston RB; Gandara DR
J Clin Oncol; 2001 Jul; 19(13):3210-8. PubMed ID: 11432888
[TBL] [Abstract][Full Text] [Related]
12. Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study.
Frasci G; Comella P; Scoppa G; Guida C; Gravina A; Fiore F; Casaretti R; Daponte A; Parziale A; Comella G
J Clin Oncol; 1997 Apr; 15(4):1409-17. PubMed ID: 9193333
[TBL] [Abstract][Full Text] [Related]
13. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
[TBL] [Abstract][Full Text] [Related]
14. [Cost-effectiveness analysis comparing carboplatin and weekly paclitaxel with cisplatin and docetaxel in the treatment of advanced non-small cell lung carcinoma].
Inage S; Ise Y; Obayashi M; Katayama S; Gemma A
Gan To Kagaku Ryoho; 2010 Nov; 37(11):2093-100. PubMed ID: 21084806
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.
Wozniak AJ; Crowley JJ; Balcerzak SP; Weiss GR; Spiridonidis CH; Baker LH; Albain KS; Kelly K; Taylor SA; Gandara DR; Livingston RB
J Clin Oncol; 1998 Jul; 16(7):2459-65. PubMed ID: 9667264
[TBL] [Abstract][Full Text] [Related]
16. Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer.
Khuri FR; Rigas JR; Figlin RA; Gralla RJ; Shin DM; Munden R; Fox N; Huyghe MR; Kean Y; Reich SD; Hong WK
J Clin Oncol; 2001 May; 19(10):2626-37. PubMed ID: 11352954
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Morrissey LH; Thomas M; Erland JB; Butts JA; Joseph G; Kalman L; Greco FA
Cancer J; 2000; 6(3):151-6. PubMed ID: 10882330
[TBL] [Abstract][Full Text] [Related]
18. [Cost-effectiveness analysis: a reader's guide].
Vergnenègre A
Rev Mal Respir; 2003 Feb; 20(1 Pt 1):116-25. PubMed ID: 12709640
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer.
Ceresoli GL; Gregorc V; Cordio S; Bencardino KB; Schipani S; Cozzarini C; Bordonaro R; Villa E
Lung Cancer; 2004 May; 44(2):231-9. PubMed ID: 15084388
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
Hainsworth JD; Greco FA
Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
